Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Promising approaches and clinical trials in MDS

A number of promising therapeutic approaches are under investigation for the treatment of myelodysplastic syndromes (MDS). We got on update on these exciting developments from David Steensma, MD, of the Dana-Farber Cancer Institute, Boston, MA, at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX. Dr Steensma highlights the potential combination of hypomethylating agents with immunotherapies such as checkpoint inhibitors, or the BCL2 inhibitor venetoclax. He also expresses his excitement for the telomerase inhibitor imetelstat and APR-246, which targets p53, before briefly mentioning the potential for CAR T-cells in MDS.